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Personality traits have been shown to interact with environmental cues to modulate biological responses including treatment responses,
and potentially having a role in the formation of placebo effects. Here, we assessed psychological traits in 50 healthy controls as to their
capacity to predict placebo analgesic effects, placebo-induced activation of m-opioid neurotransmission and changes in cortisol plasma
levels during a sustained experimental pain challenge (hypertonic saline infused in the masseter muscle) with and without placebo
administration. Statistical analyses showed that an aggregate of scores from Ego-Resiliency, NEO Altruism, NEO Straightforwardness
(positive predictors) and NEO Angry Hostility (negative predictor) scales accounted for 25% of the variance in placebo analgesic
responses. Molecular imaging showed that subjects scoring above the median in a composite of those trait measures also presented
greater placebo-induced activation of m-opioid neurotransmission in the subgenual and dorsal anterior cingulate cortex (ACC),
orbitofrontal cortex, insula, nucleus accumbens, amygdala and periaqueductal gray (PAG). Endogenous opioid release in the dorsal ACC
and PAG was positively correlated with placebo-induced reductions in pain ratings. Significant reductions in cortisol levels were observed
during placebo administration and were positively correlated with decreases in pain ratings, m-opioid system activation in the dorsal ACC
and PAG, and as a trend, negatively with NEO Angry Hostility scores. Our results show that personality traits explain a substantial
proportion of the variance in placebo analgesic responses and are further associated with activations in endogenous opioid
neurotransmission, and as a trend cortisol plasma levels. This initial data, if replicated in larger sample, suggest that simple trait measures
easily deployable in the field could be utilized to reduce variability in clinical trials, but may also point to measures of individual resiliency in
the face of aversive stimuli such as persistent pain and potentially other stressors.
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Certain personality traits are thought to influence behavior-
al risk/resiliency and have been further associated with
treatment responses in some neuropsychiatric disorders,
such as Major Depression and Bipolar Disorder (eg,
Neuroticism/Extraversion) (Quilty et al, 2009) or substance
use disorders (eg, Impulsivity/Deliberation) (Reske and
Paulus, 2008). Furthermore, personality traits such as
extraversion have been linked with placebo responses in
patients diagnosed with irritable bowel syndrome, but only
in the context of warm empathic interactions with the care
provider (Kelley et al, 2009). These data suggest that
personality variables interact with environmental (ie, social)
cues to modulate behavioral and biological placebo
responses.
Initial, largely inconclusive studies attempted to discover
a psychological profile of placebo responders in clinical
trials (Lasagna et al, 1954; Liberman, 1962). More recently,
and in the context of placebo analgesia, trait optimism and
trait anxiety were found to be positive and negative,
reproducible predictors (Geers et al, 2010; Morton et al,
2009). Dopaminergic mechanisms have been associated
with motor placebo responses in Parkinson’s disease (de la
Fuente-Fernandez et al, 2001) and with placebo analgesia
during experimental pain (Scott et al, 2007, 2008), and has
been suggested that placebo responses may represent a
form of reward responding based on positive expectations.
Consistent with that premise, a composite of personality
traits thought to be related to dopaminergic function
(novelty seeking, harm avoidance, behavioral drive, fun
seeking and reward responsiveness) have been associated
with both placebo analgesic effects and gray matter density
in the basal ganglia and prefrontal cortex (Schweinhardt
et al, 2009). In addition, neurotransmitter systems known to
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be involved in placebo analgesia (Scott et al, 2008), such as
the dopamine D2/D3 (Buckholtz et al, 2010) and m-opioid
(Love et al, 2009) have been associated with individual
differences in personality traits such as impulsivity receptor
in positron emission tomography (PET) imaging studies.
There is a substantial interest in the development of
simple measures that may provide predictive value for the
formation of placebo effects, as such effects can be quite
prominent in clinical trials. However, meta-analyses
have suggested that placebo effects are mostly observed
when the outcome measures utilized were continuous and
subjective; this is to be expected for states for which no
objective marker of disease or severity is known or is
impractical to employ in large scale trials (Hrobjartsson and
Gotzsche, 2001).
The present work examines a number of traits for their
potential association with placebo analgesia. A partial
least squares (PLS) regression approach was followed
by a leave-one-out cross-validation to select the most
predictive trait measures. Once selected, we examined them
for their association with objective measures of placebo
effects, such as placebo-induced changes in plasma cortisol
and the activation of endogenous opioid neurotransmission
using PET and a selective radiotracer labeling m-opioid
receptors. In addition to their potential utility in reducing
response variability in clinical trials, we hypothesized that
personality variables associated with the formation of
placebo effects may also point to factors that promote
resiliency from allostatic challenges to the organism, given
the known role of the m-opioid system and the
hypothalamic–pituitary–adrenal axis in the maintenance
of homeostasis during various forms of stress, including
sustained pain.
MATERIALS AND METHODS
Subjects and Psychological Inventories
Fifty right-handed, non-smoking healthy volunteers were
recruited via advertisement (Supplementary Material 1).
Forty-seven subjects completed psychological inventories
chosen to succinctly reflect various trait dimensions (data
was missing in three subjects), 19 males, 28 females, 26±5
years of age, range 19–38. A written informed consent was
obtained in all cases. All of the procedures used were
approved by the University of Michigan Investigational
Review Board for Human Subject Use and the Radioactive
Drug Research Committee.
As our primary hypothesis stated that personality
predictors of placebo responses would be associated with
stress resiliency, the following questionnaires were in-
cluded: scales assessing emotional well-being, psychological
well-being and social well-being (Keyes, 1998), dispositional
optimism (Life Orientation Test-Revised) (Scheier et al,
1994), satisfaction with life (Satisfaction with Life Scale)
(Pavot et al, 1991) and Ego-Resiliency (ER-89) (Block and
Kremen, 1996).
Personality traits related to dopaminergic function that
have been associated with placebo analgesic effects
(Schweinhardt et al, 2009) were also evaluated using the
behavioral inhibition scale/behavioral activation scale (Re-
ward Responsiveness and Drive) (Carver and White, 1994).
Low anticipatory responses to pain have been associated
with the subsequent formation of placebo analgesia (Wager
et al, 2004), therefore trait anxiety was included in the
model as a potential negative predictor (State-Trait Anxiety
Inventory) (Spielberg, 1983).
Finally, an overall evaluation of personality traits
was included using the scores of the five dimensions of
the NEO Personality Inventory-Revised (Costa and McRae,
1992a).
Quantitative Analyses
For univariate analysis, simple linear regression was used
to explore the relationship between placebo analgesia
responses (average reductions in pain intensity ratings
acquired every 15 s during the pain challenge, over
20 min) and the 15 potential psychological predictors of
placebo analgesia described above. Within the NEO
Personality Inventory-Revised, Agreeableness and Neuro-
ticism were the only dimensions significantly associated
with placebo analgesic effects in the univariate analysis;
therefore, these two domains were decomposed into their
component facets, creating an overall initial potential
predictor space of 25 variables.
For multivariate analysis, because of the presence of
multi-colinearity in the predictor space, a PLS regression
approach was used (Wold, 1966). For variable selection, a
leave-one-out cross-validation procedure was used to
extract the most significant variables from the predictor
space and x-scores were computed as a function of the
number of variables retained with the goal of minimizing
the root mean squared error of the prediction (RMSEP) (Le
Cao et al, 2008; Maitra and Yan, 2008) (Supplementary
Material). In addition to R2 that measures goodness-of-fit,
cross-validated R2 (or Q2) was computed to provide a
measure of goodness-of-prediction, and is defined as 1
(Wold et al, 2001).
Experimental Design and Neuroimaging Methods
As previously described (Scott et al, 2008), two 90-minute
[11C] carfentanil PET studies were acquired per subject, part
of a larger study where four pain administrations took place
(two pairs of pain and placebo studies, randomized in order
and counterbalanced). Subjects were placed in the scanner
gantry with needles placed in both masseter muscles
B30 min before radiotracer administration. Each scanning
session consisted of a control condition (0.9% isotonic
saline, 5-25 min after start of scanning) and a painful
condition (5% hypertonic saline, 45–65 min after start of
scanning), infused in the masseter muscle with and without
placebo administration. Once the individual infusion
profiles were established for maintenance of pain during
the hypertonic saline challenge, they were repeated during
the pain and painþ placebo studies. An average infusion
profile calculated from previous studies was utilized for the
isotonic saline challenges. Volunteers were told that these
two conditions would take place, but not the order in which
they would take place, allowing for expectation of pain
during the non-painful isotonic saline infusion (control
condition). The placebo condition consisted of the intro-
duction of 1 ml of 0.9% isotonic saline into one of the
Personality predictors of placebo analgesia
M Peciña et al
640
Neuropsychopharmacology
intravenous ports every 4 min starting 2 min before the pain
anticipation and the pain challenges in view of the
volunteer, and lasting for 15 s each time (Figure 3,
Supplementary Material).
Levels of expectancy and subjectively assessed placebo
effectiveness were also measured with the questions: ‘From
0 to 100 how effective do you think the treatment will be?’
and ‘From 0 to 100 how effective was the treatment?’.
In order to evaluate placebo effects, subjects completed
the Positive and Negative Affectivity Scale (PANAS)
(Watson et al, 1988) before and after each of the challenges,
a visual analog scale (VAS) of pain intensity every 15 s
during the pain challenge (both during control and pain
periods) and the McGill Pain Questionnaire (MPQ)
(Melzack and Torgerson, 1971) at the completion of the
pain challenge. Changes in the VAS measure in the absence
and presence of placebo were used for the assessment of
placebo responses. This variable was normally distributed
and residuals from the regression models were randomly
scattered, which validated the assumptions of the linear
models.
Data Analysis
To examine the effects of personality traits on placebo-
induced m-opioid system activation (reductions in the
receptor availability measure, nondisplaceable binding
potential (BPND), from the control—when pain is expected
but not received—to the controlþ placebo condition and
pain to painþ placebo conditions), we performed a median
split of the personality x-scores resulting from the PLS
regression approach described above. A mixed model of
analysis of variance was applied on a voxel-by-voxel basis
using Statistical Parametric Mapping software (Wellcome
Department of Cognitive Neurology, University College,
London, England), with High and Low personality x-score
groups as the between subject factor and the change in BPND
as the dependent variable. Sex and age were included in the
analysis as nuisance covariates. No global normalization
was applied to the data, and therefore the calculations
presented are based on absolute Bmax/Kd estimates. A
cortical mask that excluded the cerebellum was used in the
analysis. Only voxels with specific m-opioid receptor
binding were including in the analyses (BPND 40.1) to
reduce statistical noise. Among these regions, which are
widely distributed throughout the human brain, we
hypothesized that activation would be found in the
following regionsthat are associated with placebo analgesia:
periaqueductal gray (PAG), rostral, dorsal and subgenual
anterior cingulated cortex (ACC), prefrontal cortex, insula,
thalamus, nucleus accumbens (NAc) and amygdala. These
a priori-hypothesized regions were deemed significant at a
Po0.001 uncorrected for multiple comparisons. For other
regions, a Po0.05 family wise error-corrected was con-
sidered significant. These data were extracted for quantifi-
cation of regional changes in BPND, graphing, correlational
analyses and the identification of potential outliers. Further
statistical analyses were performed with commercially
available statistical software (SPSS for Macintosh, version
17; SPSS, Chicago, Illinois).
Cortisol Collection and Analysis
Blood samples were collected every 10 min, starting 10 min
prior to tracer administration, over the 90 min scans.
Sixteen subjects had missing data due to poor blood
sampling and the final sample consisted of 34 volunteers.
Cortisol was assayed using the automated Immulite 1 000
chemiluminescent cortisol assay (Siemens Medical Solu-
tions Diagnostic Division) with intra- and inter-assay
variability of o5% and 7%–8%, respectively. Each pair of
scans, without and with placebo) was conducted at the same
time of day (starting at 8.30 a.m. or at 1.30 p.m.).
Significant changes in cortisol plasma levels were studied
using a paired t-test comparison between the area under the
curve (AUC) (Watamura et al, 2004) during pain and the
AUC during painþ placebo. Peak reductions in cortisol
plasma levels after placebo were used to correlate (Pearson
correlation, two-tailed, Po0.05) with the analgesic placebo
response, imaging data and personality traits using SPSS
(SPSS for Macintosh, version 17). Data are expressed as the
mean±1 SD.
RESULTS
Psychophysical Responses to Placebo Administration
Significant reductions in pain intensity ratings during
placebo administration were observed using the average
VAS acquired every 15 s (pain: 30±13; painþ placebo:
24±13; F¼ 8.86, P¼ 0.005), as well as the MPQ total score
(pain: 23±11; painþ placebo: 21±12; F¼ 5.76, P¼ 0.02).
Expectation of analgesia was rated as 48%±26, and the
subjectively assessed effectiveness was 45%±30. Expecta-
tion of placebo analgesia was not significantly correlated
with placebo response (r¼ 0.19, P¼ 0.19), while the
difference between subjectively assessed and initially
expected efficacy, which represents a measure of compar-
isons between expected and subjectively observed effects,
was correlated with placebo response (r¼ 0.38, P¼ 0.008).
These results suggest that positive expectations of placebo
analgesia, a classical mechanism for the formation of
unconditioned placebo responses (Kirsch, 1985), might
not be sufficient for the development of placebo responses.
No sex differences were observed in these measures.
Personality Univariate and Multivariate Models
Using the change in average VAS score as dependent
variable, the most predictive traits of placebo analgesia in
the Univariate model were ER, NEO Agreeableness and NEO
Neuroticism, which respectively explained 16%, 14% and
12% of the variance in placebo response (Figure 1,
Supplementary Table S1). The former two were positive
predictors, whereas the latter was a negative predictor. The
three variables were highly intercorrelated (Po0.0001 for all
pairs): ER and NEO Agreeableness, r¼ 0.56; ER and NEO
Neuroticism, r¼  0.61; and NEO Agreeableness and NEO
Neuroticism, r¼  0.53.
After decomposing NEO Agreeableness and NEO Neuro-
ticism dimensions into their facets, the multivariate model
with ER, NEO Altruism, NEO Straightforwardness and NEO
Angry Hostility (negative predictor) accounted for 25% of
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the variation in placebo analgesic responses (R2) and had a
predictive ability of 18% (Q2). The leave-one-out cross-
validation showed that the retention of these four variables
yielded to global minimum prediction error (RMSEP¼
46.95). Prediction values were reported as an x-score that
estimated how well the model explained existing data and
how well it could be expected to predict new data. A 1 SD
increase in the resulting x-score was associated with a 25%
increase in placebo response (95% confidence interval:
11.74–38.31; F¼ 14.40, P¼ 0.0004) (Figure 2).
Personality Traits and Placebo-Induced Changes in
l-Opioid Receptor Availability
The x-score dimension resulting from the multivariate
model was then related to an objective measure of placebo
response, namely placebo-induced changes in m-opioid
receptor BPND, measured during the pain expectation
(control) and during sustained pain challenge. A median
split value of the x-score was used in order to get Low and
High predictor trait groups.
During the anticipation of pain, the mixed model of
variance revealed a significant effect of personality traits
(High4Low x-score) on placebo-induced endogenous
opioid system activation in the ventral striatum, including
the NAc (x, y, z coordinates,  20, 18,  5, extent 65 mm3,
Z¼ 3.5). Activation of m-opioid neurotransmission (reduc-
tions in m-opioid BPND) in this region were, at trend level,
inversely correlated with increases in PANAS negative affect
ratings (r¼  0.25, P¼ 0.07).
During sustained pain, a significant effect of traits
(High4Low x-scores) on placebo-induced m-opioid system
activation was found in several a priori-hypothesized
regions (for all regions: Z43.5, Po0.001, kX 10 mm3):
the subgenual ACC bilaterally ((MNI coordinates x, y, z,
cluster size mm3, Z score), (left:  9, 16, 14, 307 mm3,
Z¼ 4.33; right: 4, 14, 6, 492 mm3, Z¼ 3.81)), left mid-ACC
( 11,  15, 58, 197 mm3, Z¼ 4.02), the left dorsal ACC
( 19, 29, 28, 710 mm3, Z¼ 4.08), the left orbitofrontal
cortex (OFC) ( 17, 53, 19, 101 mm3, Z¼ 4.08), bilaterally
the anterior (left:  43, 13, 19, 113 mm3, Z¼ 3.5; right: 42,
6, 18, 184 mm3, Z¼ 3.89) and posterior insula (left:  48,
 11, 5, 483 mm3, Z¼ 4.33; right: 46, 2, 1, 215 mm3,
Z¼ 4.29), the left NAc ( 8, 1,  4, 664 mm3, Z¼ 4.33), the
amygdala bilaterally (left: 19, 5,  21, 98 mm3, Z¼ 3.95;
right: 14, 0,  20, 88 mm3, Z¼ 3.85) and a brainstem region
that included the PAG ( 8, 24, 16, 193 mm3, Z¼ 4.6)
(Figure 3). Greater placebo-induced m-opioid system
activation in the high-scoring group was also noted at a
lower threshold in the thalamus ( 12,  13, 15, Z¼ 2.88,
P¼ 0.002) and the dorsolateral prefrontal cortex (43, 23, 14,
Z¼ 2.96, p¼ 0.002). No significant differences in opioid
function were observed for the opposite contrast (Low4
High x-scores).
Confirmatory analysis on extracted data showed that
endogenous opioid system activation in these regions was
significantly correlated with not only the composite
measure, but also the individual personality traits that were
most significant in the simple linear regression and PLS
regression model (Supplementary Table S2). Consistent
with the central role of the NAc in placebo analgesia (Scott
et al, 2008), the x-score dimension predicted up to 27% of
the magnitude of endogenous opioid release in the left NAc.
Regional activations of m-opioid neurotransmission dur-
ing placebo administration were significantly correlated
with reductions in experimental pain ratings as measured
with the MPQ in the dorsal ACC (MPQ total: r¼ 0.31,
P¼ 0.036; MPQ sensory: r¼ 0.31, P¼ 0.034) and PAG (MPQ
affect: r¼ 0.29, P¼ 0.048). Ratings of expectations of
analgesia were significantly correlated with the activation
of m-opioid neurotransmission in the OFC (r¼ 0.31,
P¼ 0.038).
Cortisol Plasma Levels During Placebo Administration
Ten cortisol repeated measures were used to define the AUC
during each condition. Paired t-tests comparing the AUC
during pain without placebo (115.63±11.9 mg/dl) and with
placebo (92.59±11.64mg/dl) were found significant (t¼ 18.75,
df¼ 8, Po0.001).
Placebo-induced reductions in cortisol plasma levels were
particularly pronounced early after its administration, from
min 0 to 10 and from min 40 to 50 (Figure 4). Based on
these results, the peak reduction in cortisol plasma levels at
those times was used to correlate with placebo analgesic
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Figure 1 Simple linear regression representing percent change in
Placebo Response associated with 1 SD increase in Trait Measure (with





































Figure 2 Scatterplot and least squares regression line: Percent placebo
response (change in pain intensity ratings) and standardized x-score from
the optimal PLS model: scatterplot and least squares regression line.
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effects, imaging data and traits. Significant correlations
were observed between placebo-induced reductions in
cortisol from 40 min to 50 min, and the average change in
VAS acquired every 15 s during the pain challenge (r¼ 0.52,
Po0.001), MPQ total (r¼ 0.58, Po0.001) (Figure 4), MPQ
sensory subscale (r¼ 0.51, Po0.001), and MPQ pain affect
subscale (r¼ 0.60, Po0.001). Reductions in cortisol were
also associated with m-opioid system activation in the dorsal
ACC (r¼ 0.35, Po0.04) and in the PAG (r¼ 0.33, Po0.05).
No significant relationships were observed between place-
bo-induced changes in cortisol and trait predictor variables,
with exception of a trend negative correlation with NEO
Angry Hostility trait (r¼  0.30; P¼ 0.07). No significant
relationships were observed between changes in cortisol and
PANAS ratings, imaging data or trait measures during the
control (pain expectation) condition.
DISCUSSION
The present study shows that a composite of four stable
personality traits (high ER, NEO Altruism, NEO Straight-
forwardness and low NEO Angry Hostility) predicted up to
25% of placebo analgesic responses and 27% of the NAc
m-opioid system activation during placebo administration.
Additional regions where endogenous opioid responses to
placebo administration were predicted by these personality
traits largely overlap with those identified in previous
reports as responsive to placebo administration and
involved in the regulation of the pain experience (Scott
et al, 2008; Wager et al, 2007; Zubieta et al, 2005): subgenual
ACC, dorsal ACC, OFC, anterior and posterior insula,
amygdala and, at lower thresholds, PAG, thalamus and
dorsolateral prefrontal cortex. As previously observed,
activation of m-opioid receptor mediated neurotransmission
in some of these regions were associated with reductions in
individual pain report. In addition, we found significant
reductions in cortisol plasma levels during placebo admin-
istration, which were correlated with reductions in sub-
jective pain report and m-opioid system activation in the
dorsal ACC and PAG. Although no significant relationships
were observed between the composite x-score scale and
reductions in cortisol, these were negatively correlated with
NEO Angry Hostility scale scores at trend levels.
One of the positive predictors of placebo effects,
resilience, as defined by the ER-89 scale, refers to a person’s
ability to adapt successfully to acute stress, trauma or more
chronic forms of adversity (Feder et al, 2009). This trait is
thought to be mediated by positive emotions (Fredrickson
et al, 2003) and adaptive changes in reward and emotional
processing circuits (Feder et al, 2009), which may include
interactions with the endogenous opioid system (Zhou et al,
2008). Animal models of stress resiliency have linked this
trait to lower levels of ventral tegmental area dopamine
neuron excitability (Krishnan et al, 2007). In humans, lower
levels of activation during expectation of reward in the NAc
and in the subgenual ACC have been observed in a sample
of resilient Special Forces soldiers, compared with a matched
control group using functional magnetic resonance imaging
























Figure 3 Upper left: experimental design. Two [11C] carfentanil scans were obtained in each subject, with and without administration of a placebo. Lower
left: regions of greater m-opioid release during placebo administration in subjects with High x-scores vs Low x-score. Upper right: x-scores correlations with
m-opioid system activation (change in m-opioid BPND) in the NAc after placebo administration. Lower right: correlations between m-opioid system activation
in the NAc during placebo and the change in pain ratings as measured with the MPQ. BPND, binding potential nondisplaceable; MPQ, McGill Pain
Questionnaire; NAc, Nucleus accumbens; PAG, Periaqueductal gray; sgACC/dACC, subgenual/dorsal Anterior Cingulate Cortex; VAS, Visual analog scale.
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dopamine have been further associated with a greater
capacity to activate endogenous m-opioid neurotransmis-
sion during a sustained painful stressor (Zubieta et al,
2003), providing a mechanism by which stress resiliency
can be associated with greater effectiveness of the placebo
through m-opioid receptor mediated neurotransmission.
Trait agreeableness, as structured in the NEO Personality
Inventory-Revised (Costa and McCrae, 1992b), includes the
personality facets trust, straightforwardness, altruism,
compliance, modesty and tender-mindedness; straightfor-
wardness and altruism were the two facets of NEO
Agreeableness that were more closely linked with placebo
responsiveness in the analyses conducted. Some authors
have related Agreeableness to prosocial motivation, dis-
positional empathy, and situational induced empathy
(Graziano et al, 2007). In the patient doctor relationship,
Agreeableness appears likely to contribute to a strong
therapeutic alliance, as well as to frank, collaborative
feedback throughout the therapeutic process. Thus, it
appears that individuals high upon this trait are particularly
well equipped to fully engage in therapeutic efforts, (Quilty
et al, 2008) and in this sense, be a good responder to
treatment, even if it is placebo (Mackenbach, 2005).
Interestingly, research in the mechanisms of empathy in
the context of pain have shown responses to observed pain
in mid-ACC and anterior insula, two key regions of the
so-called ‘shared circuits’ for pain in self and that observed
in others (Danziger et al, 2009). Given the overlapping
neurobiology of pain, reward and placebo analgesia
circuitry (Leknes and Tracey, 2008), it would not be
surprising that regions engaged in empathic responses to
others would also be involved in placebo responses. In our
data, this was reflected by positive correlations between
agreeableness and m-opioid system activation in several
midline regions (subgenual ACC, dorsal ACC and OFC) as
well as the anterior and posterior insular cortex, NAc,
amygdala and PAG. In this respect, agreeableness has also
been linked to greater effectiveness of placebo acupuncture
(Kelley et al, 2009) and empathic traits to placebo analgesia
mediated through social learning (Colloca and Benedetti,
2009). Moreover, reciprocal altruism has been related to
resilience (Charney, 2004) and the activation of brain areas
linked to reward processing (Rilling et al, 2002).
Neuroticism was, on the other hand, a negative predictor
for the formation of placebo effects. Neuroticism is
associated with the tendency to experience negative emo-
tions (Costa and McCrae, 1992b), and includes the facets
anxiety, angry hostility, depression, self-consciousness,
impulsivity and vulnerability. In our analyses, the facet
angry hostility showed the greatest negative predictability.
The negative association between angry hostility scores and
the formation of biological placebo effects is perhaps not
surprising, given the literature linking anger to lower
endogenous m-opioid receptor system function (Burns
et al, 2009; Martin del Campo et al, 1994). Neuroimaging
studies have also shown that endogenous opioid activity in
the OFC, rostral ACC, amygdala, insula and PAG regions
contribute to modulation of both pain and negative affect,
supporting the possibility that stable variations in the
function of this system may have a relationship with trait
anger–hostility and its behavioral manifestations during
stress (eg, sustained pain) (Bingel et al, 2006; Zubieta et al,
2003). In fact, it has been hypothesized that inadequate
endogenous opioid inhibitory activity in the rostral limbic
system might simultaneously lead to elevated pain sensitivity
and reduce ability to modulate anger when it is experienced
(Bruehl et al, 2009). This is consistent with our findings,
whereby anger–hostility was negatively associated with the
capacity of a placebo to activate m-opioid receptor mediated
neurotransmission within the PAG, anterior and posterior
insula, OFC, dorsal ACC, NAc and amygdala.
Previous studies have suggested that dispositional opti-
mism, as defined by the Life Orientation Test-Revised scale,
might be a predictor of placebo analgesia using experi-
mental models of phasic heat and a preconditioning
procedure to increase expectations of analgesia (Morton
et al, 2009), or cold pain (cold pressor test) without
preconditioning, where an interaction between Life Orien-
tation Test-Revised scores and experimental condition was
reported (Geers et al, 2010; Morton et al, 2009). However,
this finding was not replicated in the present study using a
sustained pain model and no preconditioning procedures.
Finally, we observed significant placebo-induced reduc-
tions in cortisol plasma levels during both, anticipation of
pain and pain. Reductions in cortisol plasma levels during
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Figure 4 Left: reductions in cortisol plasma levels (mg/dl) after placebo administration. The sustained pain challenge was administered during 20 min,
starting at 45 min scan time. Right: Pearson correlations between total MPQ scores and decreases in cortisol plasma levels (mgr/dl) during (painþ
placebo) pain condition 5 min after pain starts. Decreases in cortisol plasma levels within the first 10 min of the pain challenge during placebo
administration predicted 33% of the variance of the MPQ scores.
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were not associated with increases in endogenous opioid
neurotransmission. In the absence of pain, lowering of
cortisol plasma levels may be secondary to reductions in
anxiety (Wager et al, 2004), potentially engaging different
neurocircuitry. During the pain challenge, reductions in
cortisol plasma levels during placebo administration were
positively correlated with both placebo analgesic responses
and the activation of regional m-opioid neurotransmission
in the dorsal ACC and PAG. At a trend level, they were also
negatively correlated with the trait angry hostility. De-
creases in cortisol levels during placebo administration
could be a consequence of pain relief or part of the
endogenous opioid modulation of the hypothalamic–
pituitary–adrenal axis. Hypothalamic corticotrophin-releas-
ing hormone neurons receive direct inhibitory input from
b-endorphin producing neurons in the arcuate nucleus, but
also regulate corticotrophin-releasing hormone neurons
indirectly through noradrenergic mechanisms (Jackson
et al, 1990). Naloxone, a non-selective opioid receptor
antagonist, induces increases in adrenocorticotropic hor-
mone and cortisol levels, an effect thought to be mediated
through the blockade of b-endorphin and enkephalinergic
input to corticotrophin-releasing hormone neurons
(Bujdoso et al, 2001). In addition, it has also been shown
that the arcuate nucleus is a part of an endogenous opioid
descending pain suppressing system impacting on the
ventrolateral PAG (Sim and Joseph, 1991).
The results presented in this report suggest that a
composite of stable personality traits can be predictive of
placebo responses, explaining one-fourth of the variance in
the formation of placebo analgesic effects in healthy
volunteers. These effects were observed using subjective
pain report scales, but also objective measures, namely the
activation of endogenous opioid neurotransmission after
placebo administration. Positive predictors related to
resiliency and interpersonal function (ER, NEO Altruism,
NEO Straightforwardness) and a negative predictor (NEO
Angry Hostility) were obtained. If replicated in clinical
samples, these simple to administer measures may aid in
the interpretation of clinical trials and the stratification of
clinical research volunteers to reduce variability in ther-
apeutic responses. In addition, they may represent traits
that impact on individual variations in resiliency to physical
and emotional stressors, such as pain, and potentially other
stress-related disorders.
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